Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating ONM-501, a drug given as intratumoral injections, alone and in combination with cemiplimab, an immune checkpoint inhibitor, in patients with advanced solid tumors and lymphomas. This phase 1 study aims to find the maximum tolerated dose, minimum effective dose, and recommended dose for expansion of ONM-501. The study includes patients with various advanced cancers who have no alternative standard therapies available. The trial has three parts monotherapy dose escalation, combination therapy dose finding, and combination therapy dose expansion. ONM-501 is given once per week for three weeks followed by three weeks off, in 21-day cycles. Cemiplimab is given intravenously every three weeks during the combination phases. Dose escalation uses special methods to gradually increase doses, and after doses are established, patients will enroll in expansion cohorts for specific tumor types. Participants will have regular assessments including monitoring for side effects, blood tests to measure drug levels, and evaluation of tumor response over up to 24 months. Researchers will track treatment-emergent adverse events, dose-limiting toxicities, and serious adverse events. Outcomes such as objective response rate, duration of response, progression-free survival, and overall survival will also be recorded. The study involves close safety monitoring and follow-up throughout the treatment and observation periods.
Actively Recruiting
Long-Term Safety and Efficacy Study of Bomedemstat for Participants From Previous Bomedemstat Trials
This research aims to collect long-term safety and efficacy data for participants who have been using bomedemstat and are benefiting from it, or have achieved blood count remission in certain conditions. The study includes individuals with essential thrombocythemia ET, polycythemia vera PV, and myelofibrosis MF who have previously been in earlier bomedemstat trials. It does not involve hypothesis testing but focuses on extended monitoring. Participants will take oral bomedemstat capsules once daily for up to 10 years. The dose they start with will be the same as they used in their previous study before transitioning into this extension. This allows continuous assessment of the effects and safety of the medication over a long period. During the study, participants will be closely monitored for adverse events and any reasons for stopping treatment due to side effects. For those with ET or PV, the duration of their clinical response and remission will be tracked, as well as any progression to more severe conditions. Other outcomes include the frequency of blood clots and bleeding events. Participant involvement may last up to about 10 years, with regular assessments and safety checks throughout.
Actively Recruiting
Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.
Actively Recruiting
Researchers are evaluating DCSZ11, a monoclonal antibody, as a treatment for patients with advanced or metastatic solid tumors. This Phase 1, multicenter, open-label study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential antitumor activity of DCSZ11 both alone and in combination with pembrolizumab. The study includes patients who have relapsed or refractory tumors and have limited or no effective standard therapy options. The study has two main phases Phase 1a Dose Escalation and Phase 1b Dose ExpansionOptimization. In Phase 1a, patients receive intravenous infusions of DCSZ11 every 3 weeks either as monotherapy or combined with pembrolizumab, with doses increased to find the maximum tolerated or planned dose. Phase 1b evaluates DCSZ11 combined with pembrolizumab or standard-of-care treatments like doxorubicin for soft tissue sarcoma and tebentafusp for uveal melanoma, using designs to optimize dosing and monitor safety continuously. Participants will undergo screening that includes biopsies, imaging, and laboratory tests to confirm eligibility and monitor response. Researchers will evaluate tumor response using established criteria such as RECIST and iRECIST over one year, and follow safety and survival outcomes for up to three years. The study involves regular clinic visits, safety assessments, and monitoring for immune responses and drug levels to understand treatment effects and tolerability.
Actively Recruiting
Researchers are studying ML-016, a drug being evaluated for safety, tolerability, pharmacokinetics, and anti-tumor effects in adults with advanced or metastatic solid tumors involving the lung andor liver. This open-label, multi-center phase 12 trial includes participants whose cancer is refractory to standard treatments or for whom no curative options exist or are acceptable. The study aims to identify appropriate dosing and assess the drugs impact on tumor control. ML-016 will be given as an intravenous infusion on Day 1 of each 21-day treatment cycle. The study includes a dose-escalation phase to determine safe dosing levels, followed by a dose-expansion phase testing two dose levels in disease-specific groups. Treatment will continue until disease progression or other discontinuation criteria are met. Participants will undergo regular evaluations including blood tests for safety, vital signs, heart function assessments with electrocardiograms and echocardiograms, and imaging studies to measure tumor response. Researchers will monitor adverse events, drug levels, and various survival outcomes over time. The study duration varies based on treatment continuation and follow-up, with primary safety assessments focused on the first 21 days of treatment cycles.
Actively Recruiting
Comparing Sentinel Node Biopsy to No Lymph Node Dissection in Early-Stage Endometrial Cancer Surgery
Researchers are studying endometrial cancer, the most common gynecological cancer, focusing on the value of sentinel node biopsy SNB compared to no retroperitoneal node dissection. The study aims to assess if SNB affects patient recovery, morbidity, quality of life, healthcare costs, and disease-free survival. This Phase III randomized clinical trial addresses ongoing controversy over lymph node dissections benefits and risks in early-stage endometrial cancer treatment. Participants are randomly assigned to one of two groups one receiving total laparoscopic or robotic hysterectomy with bilateral salpingo-oophorectomy TH BSO combined with SNB using dye injections to identify sentinel lymph nodes, and the other receiving TH BSO without retroperitoneal node dissection. Some may omit ovary removal if under 45 with specific cancer features. The trial includes two stages the first with 444 patients focusing on recovery and quality of life, and the second with 316 patients evaluating disease-free survival over 4.5 years. During the study, participants undergo surgery followed by multiple assessments including quality of life questionnaires, clinical evaluations for lymphoedema and adverse events, imaging, and molecular profiling. Researchers measure recovery at 12 months and disease-free survival at 4.5 years, along with cost-effectiveness, treatment requirements, and recurrence patterns. The total participation duration extends up to 4.5 years to monitor long-term outcomes and safety.
Actively Recruiting
Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.
Actively Recruiting
Researchers are evaluating the safety and performance of the PRIMUS System, a device designed to provide neurostimulation to branches of the trigeminal and occipital nerves, for treating resistant migraine. The study focuses on patients with chronic or high-frequency episodic migraine who have not responded to multiple preventive drug therapies. It aims to assess clinical benefits and safety over a 12-week period. Participants will be randomly assigned in a double-blind manner to one of several groups including active therapy modalities or sham therapy. The PRIMUS System delivers subcutaneous neurostimulation, and the study compares different therapy approaches to evaluate their effects on migraine symptoms. The study is set to run from June 2024 to January 2029. During the study, participants will be monitored over 12 weeks to evaluate both safety and effectiveness. Researchers will assess clinical outcomes related to migraine treatment, with follow-ups as per study protocols. This period will involve treatment administration and regular evaluations to collect data on responses and any side effects experienced.